• Vertex CEO on big cystic fibrosis breakthrough     Tuesday, 24 Jun 2014 | 3:37 PM ET

    CNBC's Meg Tirrell speaks to Vertex Pharmaceuticals CEO Dr. Jeffrey Leiden, about its promising two-drug cystic fibrosis treatment, and what it means for sufferers of the disease. Leiden also explains what goes into the pricing of an "orphan drug."

  • Vertex soars on cystic fibrosis innovation     Tuesday, 24 Jun 2014 | 10:54 AM ET

    CNBC's Meg Tirrell reports Vertex Pharmaceuticals' cystic fibrosis combination of Kalydeco and Lumacaftor has expanded their patient population.

  • Vertex's cystic fibrosis breakthrough     Tuesday, 24 Jun 2014 | 9:08 AM ET

    CNBC's Meg Tirell reports Vertex Pharmaceuticals' treatment for cystic fibrosis has succeeded in late stage trials. Vertex will now file applications for U.S. and Europe approval in Q4.

  • Cubist advances Sivextro     Monday, 23 Jun 2014 | 3:38 PM ET

    Michael Bonney, Cubist Pharmaceuticals CEO, discusses the FDA's approval of Sivextro, a new antibiotic designed to treat skin infections. Bonney also explains why so many pharma companies have left the antibiotic space.

  • CNBC's Meg Tirrell reports on everything investors need to know about Vertex Pharmaceuticals' upcoming data release on a combination of drugs for cystic fibrosis.

  • Giving cells instructions to fight disease Tuesday, 17 Jun 2014 | 6:00 AM ET
    Stéphane Bancel, president and founding CEO, Moderna Therapeutics

    AstraZeneca has invested $240 million in Moderna Therapeutics to license its technology, which uses messenger RNA therapy to fight cancer.

  • Medtronic moves to reincorporate in Ireland     Monday, 16 Jun 2014 | 4:40 PM ET

    Medtronic announced that it has agreed to purchase Dublin, Ireland's Covidien for $42.9 billion in cash and stock. CNBC's Meg Tirrell discusses why this deal may be more about taxes than medical devices.

  • Analyzing Medtronic-Covidien deal     Monday, 16 Jun 2014 | 2:21 PM ET

    Medtronic bought Covidien for $42.9 billion. Shagun Chadha, CRT Capital Group, discusses what this means for investors and explains the tax savings component of the transaction.

  • Merck's big buy     Monday, 9 Jun 2014 | 2:12 PM ET

    CNBC's Meg Tirrell reports Merck is buying Idenix Pharmaceuticals for $3.85 billion. CNBC contributor Herb Greenberg provides insight on the important deal.

  • Expectations for new obesity drug     Monday, 9 Jun 2014 | 1:39 PM ET

    New diet pill drug Contrave is expected to be approved by the FDA this week, reports CNBC's Meg Tirrell.

  • A new Clovis cancer drug has been associated with high blood sugar and linked to diabetes in trial. CEO Patrick J. Mahaffy, Clovis Oncology, weighs in on the recent report.

  • Clovis Oncology CEO: Competing with AZN     Monday, 2 Jun 2014 | 4:32 PM ET

    Clovis Oncology CEO Patrick J. Mahaffy, talks about competing with larger companies like AstraZeneca when it comes to new cancer drugs. You compete on data, he says.

  • CNBC biotech & pharma reporter Meg Tirrell talks to Richard Pazdur, the FDA's cancer czar about how far we've come in cancer treatment, breakthrough designations and if chemotherapy will soon be a thing of the past.

  • ASCO cancer care conference kicks off     Friday, 30 May 2014 | 1:01 PM ET

    In the U.S., half of all men and a third of all women will develop cancer in their lifetimes. CNBC's Meg Tirrell reports which stocks analysts are eyeing into the conference.

  • War on cancer     Thursday, 29 May 2014 | 1:38 PM ET

    The big topic at this year's cancer care conference ASCO will be immunotherapy drugs. CNBC's Meg Tirrell explains how these drugs work.

  • Valeant raises Allergan bid     Wednesday, 28 May 2014 | 10:54 AM ET

    Valeant is upping its offer for Allergan in a proposal that could now be worth more than $50 billion, reports CNBC's Meg Tirrell.

  • Why Mesoblast is big on stem-cell therapy     Tuesday, 27 May 2014 | 11:38 PM ET

    Silviu Itescu, CEO of Mesoblast, highlights sources of growth that may propel stem-cell therapy into a multi billion-dollar market by 2020.

  • How not to fear biotech     Thursday, 15 May 2014 | 1:24 PM ET

    Discussing hot picks in the biotech space, with Matthew Roden, UBS executive director.

  • Big gains for Nasdaq     Monday, 12 May 2014 | 11:59 AM ET

    CNBC's Seema Mody reveals what stocks and sectors are driving the Nasdaq rally today.

  • CNBC's Meg Tirrell speaks to Ken Frazier, Merck chaiman & CEO, about selling the company's consumer unit to Bayer. Frazier also gives his stance on mega-mergers and U.S corporate tax rate.